Meizer Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Meizer Pharma - overview
Established
2017
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Founded in 2017 and based in Shanghai, China, Meizer Pharma operates is a pharmaceutical company specializing in target protein degradation in new drugs. In January 2021, Meizer Pharma raised pre-series A funding from new investor Beijing Highthink Pharmaceutical Technology Service Co. , Ltd. Meishi Pharma's main business is targeted protein degradation new drug research and development.
It uses targeted protein degradation technology (PROTAC) to develop innovative drugs. The products can be used in the treatment of hematological tumors, solid tumors, and autoimmune disorders.
Current Investors
Yuanfu Investment, Beijing Highthink Pharmaceutical Technology Service Co., Ltd.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.